skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

​Drive commercial success

drive commerical success pharma intelligence

As a pharmaceutical company, you need to continually evaluate your disease strategy to discern gaps in your portfolio and decide whether to build or buy. Internal candidates need to be assessed against competitors’ pipelines, and assets suitable for expanding your portfolio identified. To do all this, the right data and analysis is essential.

How we can help

Our portfolio strategy solutions give you timely and accurate intelligence you can act on, including:

  • A wealth of expert insights gathered by our global team of more than 65 journalists and over 300 specialist analysts
  • The most up-to-date, comprehensive coverage of drugs, companies, epidemiology, diseases, strategy, and pricing and reimbursement trends
  • Sales forecasts for pipeline candidates and patient-based sales forecasts from surveys of more than 200 physicians per indication
  • Country-specific treatment algorithms and reimbursement scenarios
  • Comprehensive and timely market research reports to help you understand macro trends and synthesize key insights so the ‘big picture’ always informs your commercial decisions
  •  Our Ask-the-Analyst™ service that puts you in direct contact with our global analyst team

Relevant products

video-thumb-sample

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

  • Prioritize market opportunities
  • Identify unmet needs
  • Make informed decisions
video-thumb-sample

Pharmapremia: Benchmark better and optimize your drug development pipeline

Using a peer-reviewed methodology that provides robust, unbiased drug phase success rates and timeline metrics by treatment indication, Pharmapremia enables you to make strong, informed decisions about your drug development pipeline.

Key benefits:

  • Manage portfolio risks
  • Analyze success factors
  • Create meaningful benchmarks
video-thumb-sample

In Vivo: strategic insights for life sciences decision-makers

In Vivo offers comprehensive coverage of the global medical industry’s competitive landscape.

Key benefits:

  • Cutting edge thought leadership
  • Expert analysis
  • Hear from news makers

Pharma Intelligence latest insights

  • In Vivo, HBW Insight, Pink Sheet, Scrip, Generics Bulletin, ...

    Coronavirus: Keep up to date with Breaking News and Insight

    Coronavirus_Cover

    Track the latest developments in the worldwide coronavirus outbreak and what it means for the pharma, medtech, generics and OTC industries with coverage from the Informa Pharma Intelligence Insights suite of tools. Get vital breaking news and penetrating analysis about the impact of this global health crisis.

    Topic Coronavirus

  • In Vivo, Scrip

    Webinar: Is Biopharma Fit For the New Decade?

    Webinar: Is Biopharma Fit For the New Decade?

    Download your article pack now for a glimpse of some of the topics that will be covered by our panel of experts during the “Is Biopharma Fit for the New Decade?” webinar.

    Topic Cell and gene therapy Policy and regulation

  • In Vivo

    Fact File: Coronavirus Pipeline And Corporate Updates

    Corona_Invivo

    The coronavirus outbreak is at a tipping point, after which its development into a global pandemic may be unstoppable. Companies large and small have mobilized in the fight against the disease bringing new and repurposed treatment options into development and preparing their business for the unsteady months ahead.

    Topic Coronavirus

  • Biomedtracker, Datamonitor Healthcare

    2020 Early Outlook Webinar

    Anticipate the biggest, most impactful expected catalysts of early 2020 with the guidance and insights from Pharma Intelligence. Building off Biomedtracker’s Early 2020 Outlook report, our live webinar will include market context for these upcoming milestones and additional insights from Datamonitor Healthcare’s Therapeutic Area Directors.

    Topic FDA

  • In Vivo

    Regular Acceptance Of Simulation Studies More Likely In 2020s

    Robotic_head

    Lyon, France-based Novadiscovery is developing a user-facing technology to run in silico studies, a method it expects to cut development costs and improve trial success rates. But acceptance of “new” data types is often a concern for drug developers, despite world-leading regulatory bodies stating their desire for 21st century approaches.

    Topic BioPharmaceutical

  • In Vivo

    A Tale Of Two Pipelines

    A_Tale_Of_Two_Pipelines_1

    Immuno-oncology has produced some exciting successes, but the field has become intensely crowded. Enormous resources are being poured into duplicative work and shaky hypotheses—overshadowing other pursuits in cancer research while producing limited results. It is time to re-evaluate how the sector should be pursuing innovation in cancer and how it can be smarter in its use of resources—financial investment, talent, bandwidth, patients and data.

    Topic Cancer Research

  • In Vivo

    ESG In 2020: Not A Tick-Box Exercise But A Strategic Opportunity

    ESG_In_2020_1

    The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.

  • Datamonitor Healthcare

    Cardiovascular Disease Epidemiology Overview

    Inforgraphic

    Cardiovascular Diseases (CVDs) are one of the leading causes of disease burden worldwide. This epidemiology overview presents the prevalence of some CVDs and their associated clinical risk factors analyzed by Datamonitor Healthcare.

  • Biomedtracker, Datamonitor Healthcare

    2019 Post-ASH Conference Report Extract

    Report

    Access vital post-ASH meeting reporting from the expert analysts at Datamonitor Healthcare and Biomedtracker.

  • In Vivo

    Bayer US Pharmaceuticals' Sebastian Guth: Designs On A New Decade

    Bayer_US_Pharmaceuticals_Sebastian_Guth

    Bayer’s ambitious campaign to reposition itself as a global leader in two complementary fields – health and nutrition – will face its toughest test in the US, with its highly litigious approach to product liability and a tendency to target pharmaceuticals as the source of the health system’s affordability and access problems.

  • In Vivo

    Outlook 2020 Report

    Outlook_2020_Content_Tile_Image

    Tap Outlook 2020’s essential coverage of medtech, R&D, clinical trials and regulation, manufacturing, and more with your extract from our most powerful report.

  • In Vivo

    Medtechs Enter The Decade of Digital, Consumers and Wellness

    Analysis

    For providers and medtech manufacturers alike, the decade ahead will be a time of coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market entry criterion, but companies will have to adapt to evolving health care delivery models. The stakes are implausibly high. Will they be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?

  • In Vivo

    Critical Insights into Market Access

    Critical Insights into Market Access

    Your key to refining your market access strategy with essential patient market access mini-mag and infographic from the experts at In Vivo.

  • In Vivo

    Brexit To And Fro Continues Into Fresh Decade

    Analysis

    Three Brexit deadlines have come and gone, and the UK is still a member of the European Union. It will remain so until it agrees a withdrawal deal or leaves without one at the end of January 2020. Alternatively, it could secure yet another extension to the Article 50 period beyond January 31. Or it could decide not to leave at all.

    Topic Business Strategies Policy and regulation

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: